# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects

> **NCT02058407** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Bronchiectasis

## Interventions

- **DRUG:** GSK2793660 solution
- **DRUG:** GSK2793660 capsule
- **DRUG:** Placebo solution
- **DRUG:** Placebo capsule

## Key facts

- **NCT ID:** NCT02058407
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-28
- **Primary completion:** 2014-10-31
- **Final completion:** 2014-10-31
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Drug related AEs observed upon repeat dosing that with longer treatment duration could become worse. Required action on some biomarkers not observed.
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058407, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02058407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*